Partner Mary Leslie Smith was quoted in the June 4, 2013 edition of the Miami Herald in an article titled, “Advice to graduates: Combine networking with true passions.” The article offered networking and career advice to young professionals, highlighting ways in which to build the right networks, learn the right skills, and lay a foundation to become a successful leader in the future. Ms. Smith noted in the article that it is worth the time investment to build and maintain social networks, but that is only one piece of the puzzle — connecting in person builds shared experiences that strengthen relationships. She also added that building a vibrant network includes forging relationships at all levels. “Ten years from now that associate next door may be a general counsel who becomes a client. The more friendships, the more relationships you build, the better.” Ms. Smith also noted that one of the best time investments a young professional can make is financial education, particularly for those without business degrees. “Learn to read a financial statement, the key terms in the stock market, how to read a prospectus. It will pay off for you.”
People
Related News
25 July 2024
In the News
Donald Schroeder on Groff – ‘Supreme Court decision is inviting a more fact-based analysis’
Foley & Lardner LLP partner Donald Schroeder assessed the impact of the U.S. Supreme Court’s 2023 decision in a religious accommodation case as it returns to the district court in the Law360 article, “A Year After High Court Spotlight, Groff Case Still A Bellwether.”
24 July 2024
In the News
Louis Lehot Featured in Q&A on How Startups Can Prepare for IPO
Foley & Lardner LLP partner Louis Lehot features in the Q&A, "How startups can get in top shape for an IPO, according to Silicon Valley lawyer Louis Lehot," part of Business Insider's Road to IPO' series.
24 July 2024
In the News
Courtenay Brinckerhoff on Patent Cap in Drug Pricing – ‘Hard to predict if this will make a difference’
Foley & Lardner LLP partner Courtenay Brinckerhoff discussed a recent bill passed in the U.S. Senate aimed at lowering drug prices by limiting the number of patents that can be asserted in cases over biosimilars in the Law360 article, “Patent Cap In Drug Pricing Bill Seen As Having Muted Effect.”